Transition Document for the United States Patent and Trademark Office
Summary
This transition document provides over 25 actionable recommendations on the future of the United States Patent and Trademark Office (USPTO), in order to support future federal leadership and enable their success. The document is the result of collaboration between the Day One Project and a group of veteran policymakers who convened virtually to produce recommendations related to the following three categories:
- Identifying specific policy and governance ideas that can be pursued in the first days and months of the next administration.
- Gathering “lessons learned” from those who have previously served in government to learn from past challenges and better inform future initiatives.
- Understanding key science and technology staffing and “talent” needs, and related challenges for the USPTO that can be addressed in the next administration.
The document also includes a cover memo which highlights some of the overarching key considerations for the future of the USPTO.
Contributors
- Margo A. Bagley
- Sharon Barner
- Brian Cassidy
- Colleen V. Chien
- Mark Allen Cohen
- Ayala Deutsch
- Ben Haber
- Philip G. Hampton
- Justin Hughes
- David J. Kappos
- Quentin Palfrey
- Arti K. Rai
- Teresa Stanek Rea
- Robert L. Stoll
- A. Christal Sheppard
- Saurabh Vishnubhakat
- Stephen Yelderman
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.
By leveraging its substantial purchasing power responsibly, the government can encourage high-quality, inclusive AI solutions that address diverse citizen needs while setting a strong precedent for innovation and accountability.
The federal government should expand the FDA’s priority review voucher program and provide market exclusivity advantages to encourage the development of medications for addiction.